MarketPulse

bispecific antibody

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Mestag Therapeutics

Mestag Therapeutics Secures $40M to Advance FAP-Targeted Cancer Immunotherapy

Mestag Therapeutics closes $40M financing and appoints leadership to advance FAP-targeted cancer immunotherapy MST-0312 into Phase 1 clinical trials.
JNJclinical trialbispecific antibody
GlobeNewswire Inc.GlobeNewswire Inc.··Johnson & Johnson

J&J Seeks EMA Approval for TECVAYLI as First-Line Monotherapy in Multiple Myeloma

Johnson & Johnson submits EMA application for TECVAYLI monotherapy in relapsed/refractory multiple myeloma, citing 71% risk reduction in disease progression or death versus standard care.
JNJEMA approvalPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aclaris Advances Dual-Target Antibody into Asthma Study Following Dermatitis Trial Launch

Aclaris launches Phase 1b asthma trial for ATI-052, a dual-target antibody also in dermatitis trials. Results expected mid-2026.
ACRSclinical developmentatopic dermatitis
GlobeNewswire Inc.GlobeNewswire Inc.··Macrogenics, Inc.

MacroGenics Halts New Patient Enrollment in LINNET Trial Following FDA Clinical Hold

FDA places partial clinical hold on MacroGenics' LINNET trial due to serious adverse events including thrombocytopenia, myocarditis, and one death. New enrollment halted.
MGNXFDA clinical holdbispecific antibody